NEWS
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
NanoViricides (NYSE:NNVC) is investigating the use of its drug candidate NV-387 to treat MPOX under the WHO MEURI protocol, following the recent MPOX outbreak declaration. Key points:
1. NV-387 completed Phase I trials with no adverse events reported.
2. It showed strong survival improvement in animal studies, matching the approved drug tecovirimat.
3. NV-387 was found superior or equivalent to existing drugs for RSV, Influenza, and COVID in non-clinical trials.
4. The current MPOX epidemic is caused by Clade 1/1b, which is more severe than the 2022 Clade 2 outbreak.
5. NV-387 acts via 'Re-Infection Inhibition', blocking virus cell infection.
The company believes NV-387 could be revolutionary for viral infection treatment if proven effective in human trials.
1. NV-387 completed Phase I trials with no adverse events reported.
2. It showed strong survival improvement in animal studies, matching the approved drug tecovirimat.
3. NV-387 was found superior or equivalent to existing drugs for RSV, Influenza, and COVID in non-clinical trials.
4. The current MPOX epidemic is caused by Clade 1/1b, which is more severe than the 2022 Clade 2 outbreak.
5. NV-387 acts via 'Re-Infection Inhibition', blocking virus cell infection.
The company believes NV-387 could be revolutionary for viral infection treatment if proven effective in human trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2047Followers
102Following
18KVisitors
Follow